Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MicroVasc-DIVA: Rivaroxaban vs Aspirin in Type 2 Diabetes
NCT02164578Phase 3Completed
- Sponsor
- GWT-TUD
- Start
- Apr 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GWT-TUD. Primary endpoints: Post-ischemic Forearm Blood Flow at 20 weeks and Pulse Wave Velocity at 52 weeks. Started Apr 2015; status: completed.
02
Drugs
rivaroxaban
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02164578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164578.